See the DrugPatentWatch profile for Olaparib
Olaparib is currently under patent protection, with its primary patent set to expire in 2028 [1]. This patent pertains to the composition of matter for olaparib. As a result, generic versions of olaparib are not yet available in the market [1].
When can generic olaparib be expected?
Generic olaparib is anticipated to become available after the expiration of its key patents, the earliest of which is scheduled for 2028 [1]. The exact timing for the market entry of generic versions can be influenced by factors such as patent litigation and the potential for the approval of biosimilars or interchangeable generics, although olaparib is a small molecule drug, not a biologic, making biosimilarity not directly applicable.
What is olaparib used for?
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor used in the treatment of certain types of cancer. It is approved for individuals with specific genetic mutations, such as BRCA mutations, in ovarian, breast, pancreatic, and prostate cancers [2].
How does olaparib work?
Olaparib works by inhibiting PARP enzymes. These enzymes play a role in DNA repair. By blocking PARP, olaparib prevents cancer cells, particularly those with existing DNA repair defects like BRCA mutations, from repairing their damaged DNA, leading to cell death [2].
Are there any current challenges to olaparib patents?
While the primary composition of matter patent for olaparib is set to expire in 2028, other patents related to its use and formulation may exist [1]. Challenges to these patents could potentially alter the timeline for generic market entry. Information on specific patent challenges is tracked by resources like DrugPatentWatch.com [1].
What are the competitors to olaparib?
Other PARP inhibitors are available and compete with olaparib. These include drugs like niraparib, rucaparib, and talazoparib, which are also used for treating specific types of PARP-dependent cancers [2].
What are the risks or side effects associated with olaparib?
Common side effects of olaparib can include nausea, fatigue, anemia, and changes in blood cell counts [2]. More serious risks, such as myelodysplastic syndrome or acute myeloid leukemia, have also been reported [2].
Can patients access olaparib without a patent?
Currently, access to olaparib is through its branded formulation, as generic versions are not yet on the market due to patent protection [1]. Patient assistance programs may be available through the manufacturer for those who meet eligibility criteria.
Where can I find more information on olaparib patents and exclusivity?
Detailed information regarding olaparib's patent status, including expiration dates and potential challenges, can be found on specialized pharmaceutical patent tracking websites such as DrugPatentWatch.com [1].
What is the difference between olaparib and other cancer treatments?
Olaparib is a targeted therapy that exploits specific DNA repair deficiencies in cancer cells, particularly those with mutations in genes like BRCA. This differs from traditional chemotherapy, which broadly targets rapidly dividing cells, or other targeted therapies that may act on different cellular pathways [2].
Sources:
[1] https://drugpatentwatch.com/
[2] https://www.cancer.gov/